Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
Nunzia D’Onofrio, Celestino Sardu, Maria Consiglia Trotta, et al.
Molecular Metabolism (2021) Vol. 54, pp. 101337-101337
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 256
Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 172
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 147
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 124
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 80
SIRT6 in Aging, Metabolism, Inflammation and Cardiovascular Diseases
Zhenyang Guo, Peng Li, Junbo Ge, et al.
Aging and Disease (2022) Vol. 13, Iss. 6, pp. 1787-1787
Open Access | Times Cited: 72
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis
Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 60
SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells
Nunzia D’Onofrio, Francesco Prattichizzo, Raffaele Marfella, et al.
Theranostics (2023) Vol. 13, Iss. 2, pp. 531-542
Open Access | Times Cited: 53
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Celestino Sardu, Nunzia D’Onofrio, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes
Raffaele Marfella, Lucia Scisciola, Nunzia D’Onofrio, et al.
Pharmacological Research (2022) Vol. 184, pp. 106448-106448
Open Access | Times Cited: 69
Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ran Wei, Weihao Wang, Qi Pan, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 39
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Atherosclerosis (2023) Vol. 378, pp. 117180-117180
Closed Access | Times Cited: 38
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, et al.
Journal of Cardiovascular Pharmacology (2023) Vol. 81, Iss. 1, pp. 4-14
Closed Access | Times Cited: 34
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts
Yuan Gui, Zachary Palanza, Haiyan Fu, et al.
The FASEB Journal (2023) Vol. 37, Iss. 4
Open Access | Times Cited: 24
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
Jiaqi Mei, Yi Li, Liyan Niu, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Ruining Zhang, Qingxing Xie, Xi Lu, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Camilla Anastasio, Isabella Donisi, Vitale Del Vecchio, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 9
Elucidating emerging signaling pathways driving endothelial dysfunction in cardiovascular aging
Anna De Bartolo, Tommaso Angelone, Carmine Rocca
Vascular Pharmacology (2025), pp. 107462-107462
Closed Access | Times Cited: 1
Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
Celestino Sardu, Massimo Massetti, Nicola Testa, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 55
Essential Fatty Acids as Biomedicines in Cardiac Health
Igori Balta, Lavinia Ștef, Ioan Peț, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1466-1466
Open Access | Times Cited: 46
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study
Celestino Sardu, Massimo Massetti, Pietro Rambaldi, et al.
Metabolism (2022) Vol. 137, pp. 155243-155243
Open Access | Times Cited: 38
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Panagiotis Theofilis, Μarios Sagris, Evangelos Oikonomou, et al.
Diabetes Research and Clinical Practice (2022) Vol. 188, pp. 109927-109927
Closed Access | Times Cited: 30
Diabetes Mellitus to Accelerated Atherosclerosis: Shared Cellular and Molecular Mechanisms in Glucose and Lipid Metabolism
Nan Zhao, Xiaoting Yu, Xinxin Zhu, et al.
Journal of Cardiovascular Translational Research (2023) Vol. 17, Iss. 1, pp. 133-152
Closed Access | Times Cited: 20
SGLT2 breast expression could affect the cardiovascular performance in pre-menopausal women with fatty vs. non fatty breast via over-inflammation and sirtuins’ down regulation
Celestino Sardu, Gianluca Gatta, Gorizio Pieretti, et al.
European Journal of Internal Medicine (2023) Vol. 113, pp. 57-68
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top